Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CBX7 | O95931 | 1/20 | 0.37 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.37 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 4/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4109394 | 1.00 | KDM4E (0.48) | KDM4EALDH1A1MAPK1HTTHSD17B10 | |
| SCHEMBL4109405 | 1.00 | KDM4E (0.48) | KDM4EALDH1A1MAPK1HTTHSD17B10 | |
| SCHEMBL4110870 | 1.00 | KDM4E (0.48) | KDM4EALDH1A1MAPK1HTTHSD17B10 | |
| SCHEMBL4096195 | 0.88 | HSD17B10 (0.45) | KDM4EALDH1A1MAPK1HTTHSD17B10 | |
| SCHEMBL4116759 | 0.88 | HSD17B10 (0.45) | KDM4EALDH1A1MAPK1HTTHSD17B10 | |
| SCHEMBL4096199 | 0.88 | HSD17B10 (0.45) | KDM4EALDH1A1MAPK1HTTHSD17B10 | |
| SCHEMBL4116751 | 0.88 | HSD17B10 (0.45) | KDM4EALDH1A1MAPK1HTTHSD17B10 | |
| SCHEMBL3988515 | 0.81 | KDM4E (0.55) | KDM4EALDH1A1MAPK1HTTHSD17B10 | |
| SCHEMBL4115615 | 0.80 | KDM4E (0.38) | KDM4EALDH1A1MAPK1HTTHSD17B10 | |
| SCHEMBL4115609 | 0.80 | KDM4E (0.38) | KDM4EALDH1A1MAPK1HTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802300-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-05-27 | — | — | EP | claimed |
| EP-1802300-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2007-07-04 | — | — | EP | claimed |
| WO-2006044232-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | claimed |
| EP-1802300-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080097108-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2008-04-24 | — | — | US | disclosed |
| EP-1802300-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044232-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097108-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNH2, KCNN1, KCNH3 | KDM4E 1326/4885ALDH1A1 979/4885MAPK1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.